SAN DIEGO, Nov. 12, 2017 /PRNewswire/ -- ResMed (NYSE:
RMD, ASX: RMD) today issued the following statement from
David Pendarvis, the company's
global general counsel and chief administrative officer:
"While we are disappointed the English Patents Court has ruled
that ResMed's patent EP 2 708 258 is invalid in the UK, we are
pleased by the court's unambiguous statement regarding our
assertion that Fisher & Paykel's Simplus and Eson masks
infringe ResMed's patent. The English Patents Court said, 'Had it
been valid it would have been infringed.' We appreciate the court's
attention to this matter, and we are considering an appeal.
The ruling has no impact on ResMed's commercial operations in
the UK. All of our products will continue to be available there
with customer service support. Likewise, the ruling is limited only
to the UK and has no impact on ResMed's pending cases against
Fisher & Paykel in the United
States, New Zealand or
Germany. We are confident that
when the courts in those countries apply their different
evidentiary rules and validity procedures, we will prevail."
About ResMed
ResMed (NYSE: RMD, ASX: RMD) changes
lives with award-winning medical devices and cloud-based software
applications that better diagnose, treat and manage sleep apnea,
chronic obstructive pulmonary disease (COPD) and other chronic
diseases. ResMed is a global leader in connected care, with more
than 4 million patients remotely monitored every day. Our
6,000-strong team is committed to creating the world's best
tech-driven medical device company – improving quality of life,
reducing the impact of chronic disease, and saving healthcare costs
in more than 120 countries. ResMed.com | Facebook | Twitter |
LinkedIn
For
media:
|
For
investors:
|
Alison
Graves
|
Agnes Lee
|
+1-858-836-6789
|
+1-858-836-5971
|
news@resmed.com
|
investorrelations@resmed.com
|
Logo -
https://mma.prnewswire.com/media/588826/RESMED_INC__LOGO.jpg